Novo Nordisk introduces "There's Only One Ozempic®" campaign, reuniting Justin Long and John Hodgman
PLAINSBORO, N.J., Jan. 20, 2026 /PRNewswire/ -- Novo Nordisk today announced the launch of a new consumer campaign for Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, reinventing how traditional pharma advertising is being done. The campaign features the celebrated comedy pairing of actors Justin Long and John Hodgman, who first appeared together in a series of popular TV commercials in the mid-2000s. In this new campaign the duo combine levity, lively banter, and everyday moments to encourage informed and impactful dialogue between people living with type 2 diabetes and their doctors about GLP-1 treatment options.
Experience the full interactive Multichannel News Release here: https://www.multivu.com/novo-nordisk/9378751-en-novo-nordisk-theres-only-one-ozempic-campaign
While Ozempic ® is now a household name, by taking this unique, patient-focused approach, the campaign aims to educate on all the FDA-approved uses for Ozempic ® and how this differentiates this iconic brand from other GLP-1s for the treatment of type 2 diabetes and unapproved compounded "semaglutide."
"Not all GLP-1s are the same, and people with type 2 diabetes should talk with their doctors about whether Ozempic ® is right for them," said Ed Cinca, Senior Vice President, Marketing & Patient Solutions at Novo Nordisk Inc. "With our campaign, we're cutting through the noise with straightforward education about how Ozempic ® fits into care. Ozempic ® is the only FDA-approved GLP-1 that improves blood sugar along with diet and exercise and reduces the risk of major cardiovascular events and worsening kidney disease - key information that can make a real difference when choosing a type 2 diabetes treatment."
The "There's Only One Ozempic ®" campaign uses relatable storytelling and well-known voices to help information stand out in a crowded category and encourages people to look beyond surface-level familiarity with GLP-1s, seek credible information, and have more significant conversations about which FDA-approved treatments for type 2 diabetes may be right for them.
This new consumer campaign is educating patients on the differences between GLP-1s and underscoring Novo Nordisk's commitment to keeping them at the center. With the most FDA-approved uses among GLP-1s for type 2 diabetes, Ozempic ® is an injectable prescription medicine used to improve blood sugar along with diet and exercise for adults with type 2 diabetes, to reduce the risk of major cardiovascular events (heart attack, stroke, or death) in adults with type 2 diabetes and known heart disease, and to reduce the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. Ozempic ® is not approved for use in children. Given the vast amount of information on knock-off or compounded "semaglutide" being shared in the media, it is important for healthcare professionals and patients to have the clarity and confidence in knowing what they are using has undergone rigorous review for safety, effectiveness, and quality. Only Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic ®. If the label doesn't say Ozempic ®, it's not FDA-approved.
Check out one of the first episodes in the campaign series:
"Humor has a way of opening the door to conversations people might otherwise avoid," said Justin Long. "This campaign uses that idea thoughtfully and meets people where they are consuming content while helping them feel comfortable enough to learn more about their health." John Hodgman added, "It's important for people to learn more about their medication options and have that discussion with their doctors. What I appreciate about this campaign is the way it encourages meaningful conversations that can truly make a difference." Justin Long and John Hodgman are paid spokespeople for Novo Nordisk, and they do not live with type 2 diabetes, or take Ozempic ®.
Important Safety Information
Do not share your Ozempic ® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
What is the most important information I should know about Ozempic ®?
Ozempic ® may cause serious side effects, including:
Do not use Ozempic ® if:
Before using Ozempic ®, tell your health care provider if you have any other medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas.
What are the possible side effects of Ozempic ®?
Ozempic ® may cause serious side effects, including:
The most common side effects of Ozempic ® may include nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation.
What is Ozempic ®?
Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:
It is not known if Ozempic ® is safe and effective for use in children.
Please click here for Prescribing Information and Medication Guide for Ozempic ®.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
Contacts for further information
Media:
Liz Skrbkova (US)
+1 609 917 0632
[email protected]
Ambre James-Brown (Global)
+45 3079 9289
[email protected]
Investors:
Frederik Taylor Pitter (US)
+1 609 613 0568
[email protected]
Jacob Martin Wiborg Rode (Global)
+45 3075 5956
[email protected]
Sina Meyer (Global)
+45 3079 6656
[email protected]
Ida Schaap Melvold (Global)
+45 3077 5649
[email protected]
Max Ung (Global)
+45 3077 6414
[email protected]
SOURCE Novo Nordisk